CSL Behring, a rare disease biotech company, is relying on a Booklet-Label and Flexi-Cap label combination developed by Schreiner MediPharm to conduct an international Phase III study of a new immunoglobulin.
CSL Behring is using transparent containers with a flip-off cap for the latest immunoglobulin clinical trial. Due to visible differences between the verum and the placebo, the containers with the trial drugs must be blinded so that trial participants are unaware of what is being dispensed to them. Additionally, the trial is being conducted on an international scale, so product descriptions must be available in several languages.
Schreiner’s experts developed a special version of its Flexi-Cap technology to blind the vials with two opaque-printed, silver-colored film caps. The first wraps around the closure and the upper part of the container without covering the flip-off cap, and the second, which covers the lower part and bottom of the container.
Moreover, a multi-page Booklet-Label attached to the vial provides comprehensive product descriptions in several languages.
The construction of the caps plus Booklet-Label is affixed manually using special application tools and can be flexibly adapted to diverse vial sizes and shapes.
Compared to other label options, which are complex to apply and can be easily peeled off, this combination of Schreiner’s technologies offers fast and reliable blinding combined with clear and efficient marking of the vials.
August 13, 2020 at 04:24PM
https://ift.tt/2DHD7PY
Schreiner develops label combination for immunoglobulin trial - Labels and Labeling
https://ift.tt/3fbzbE8
Bagikan Berita Ini
0 Response to "Schreiner develops label combination for immunoglobulin trial - Labels and Labeling"
Post a Comment